Skip to content

Study of Neurological Damage From Coronavirus Disease (COVID-19)

Study of Neurological Damage From Coronavirus Disease (COVID-19): Extraction of Quantitative Imaging Biomarkers for the Characterization of Pathological Profiles

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05079373
Acronym
NeuroBiomarK
Enrollment
250
Registered
2021-10-15
Start date
2021-04-01
Completion date
2022-10-31
Last updated
2021-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, SARS-COV-2, Central nervous system, Headache, Loss of smell, Coma

Brief summary

The objective of this study is to support the exploration of the NEURO-COVID-19 database and in particular to carry out the post-treatments necessary to derive quantitative information on the characterization of the lesion load, in particular with regard to of the vascular tree

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * COVID + patient presenting with neurological symptoms leading to an MRI. * Patient taken care of in one of the care centers associated with this research * Patient not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria

* Patient who expressed his opposition to participating in the study * COVID patient not having neurological symptoms or not having received an MRI * Patient under guardianship or guardianship * Patient under legal protection

Design outcomes

Primary

MeasureTime frame
Retrospective study of the neurological damage in patients with Covid-19Files analysed retrospectively from January 01, 2020 to October 31, 2021 will be examined]

Countries

France

Contacts

Primary ContactStephane Kremer, MD, PhD
stephane.kremer@chru-strasbourg.fr33 3 88 12 78 89
Backup ContactSaïd CHAYER, PhD, HDR
said.chayer@chru-strasbourg.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026